Bio

Jean Gabriel Griboul has extensive experience in venture and growth capital, private equity, public and private M&A, and capital markets transactions. Jean-Gabriel primarily represents high-growth listed and unlisted companies, their managers, as well as the private equity and industrial investors that finance them. He has acted as principal lawyer in a significant number of early to late-stage financing rounds, M&A transactions, initial public offerings (IPOs), rights issues, tender offers, and private placements, mainly for technology and life sciences companies. Jean-Gabriel's recent experience includes the representations of: Adikteev, Adocia, AudioValley, Cubyn, Mauna Kea Technologies, Nanobiotix, Swile, TxCell, Verimatrix, and Voluntis. His recent investor-side representations include: Alven, BNP Paribas, Bpifrance, ChapsVision, Daphni, DN Capital, Elaia Partners, ETF Partners, Eurazeo/Idinvest, Goldman Sachs, Hedosophia, Index Ventures, Invus, New Alpha Asset Management, Omnes Capital, Open CNP, Orange, Portag3 Ventures, and Seventure Partners. Examples of the transactions in which Jean-Gabriel has acted as lead lawyer include: the Nasdaq IPO of Nanobiotix; ChapsVision tender offer on Coheris; the sale of Drivy to Getaround; financings rounds of Swile; and Orange's investments in Jumia (AIG).